DEVELOPMENT OF A PERSONALIZED TECHNIQUE FOR EARLY DIAGNOSIS AND PREDICTION OF VARIANTS OF THE COURSE OF HYPERTROPHIC CARDIOMYOPATHY BASED ON THE ANALYSIS OF MICRORNAS-21, 29A, 133A

For many years, cardiovascular diseases have occupied and continue to occupy leading positions due to mortality and disability of the adult working-age population. Hypertrophic cardiomyopathy (HCM) is the most common variant of cardiomyopathy, its prevalence among the general population worldwide is 0.2% (1 in 500 adults). The study of the disease has been taking place for quite a long time, the half-century history of studying the problem of HCMP reflects a significant evolution of knowledge in matters of etiology, pathogenesis, diagnosis, clinical course and prognosis, variants of the course of the disease, however, there are still no methods of early diagnosis that could be used as a possible screening of this condition in the early stages and forecasting its more severe course. New methods could make it possible to diagnose this condition at an early stage and predict a possible course of its course, thereby preventing such a formidable complication as sudden cardiac death (SCD). At the moment, there is a prediction model (HCM Risk-SCD) for the risk of SCD, based on the results of instrumental research methods and anamnesis data of a particular patient, but this model is not perfect enough, and therefore it is gaining great popularity and the search for various biomarkers continues based on well-known scientific achievements in the field of genomics and transcriptomics. Perhaps in the near future, the study of the levels of certain microRNAs, which have already proven their affinity for the degree of myocardial hypertrophy, will become a new milestone in the study of hypertrophic cardiomyopathy.